Navigation Links
For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
Date:12/7/2009

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options finds that more than half of surveyed oncologists in Germany, France and Spain indicate that the existence of a validated biomarker for Erbitux has decreased their prescribing of Avastin in a subpopulation of patients with metastatic colorectal cancer. Sales of Erbitux in these countries will be driven by its use to treat patients with wild-type KRAS (Kirsten rat sarcoma 2 viral oncogene) metastatic colorectal cancer. However, the existence of a validated biomarker for Erbitux has not had a significant impact on the prescribing of Avastin in Italy, which is likely due to the currently low levels of KRAS testing in this country.

"More than half of oncologists in France and Italy say they use Avastin-containing regimens as first-line treatment in patients known to have wild-type KRAS metastatic colorectal cancer, despite a valid biomarker proving the efficacy of Erbitux in this population," said Decision Resources Analyst Marcus Hoyle, B.Sc. "However, in Spain, the majority of oncologists say they use Erbitux-containing regimens in this setting, which is most likely due to the high levels of KRAS testing in Spain as compared to other countries."

The report finds that reimbursement of KRAS testing varies between the European countries surveyed. In France and Spain, KRAS testing is reimbursed but i
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  InMed Pharmaceuticals ... stage biopharmaceutical company that specializes in developing safer, ... of Paul C. Anderson , Ph.D., to ... pharma industry veteran who brings significant drug discovery ... Anderson is a synthetic organic chemist by training ...
(Date:3/31/2015)... -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) ... and 300mg oral tablets, indicated for use in the ... Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 ... Arthur S. Przybyl , President and Chief Executive Officer ... our fourth product from the portfolio of approved generic ...
(Date:3/31/2015)... March 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) ... and commercialization, announced today Oxis CEO Tony Cataldo ... Oxis common shares on the Euronext exchange. Oxis shares ... symbol OXIS.   Oxis Chairman and CEO ... move forward with its strategies launched in 2014 and ...
Breaking Medicine Technology:InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Oct. 7 Cleveland Clinic,s Top 10 Medical Innovations for ... therapies that are being developed to treat everything from deafness ... The list of breakthrough devices and therapies was selected by ... was unveiled during Cleveland Clinic,s 2009 Medical Innovation ...
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... offering of 3.97 million shares of its common stock to ... gross proceeds of $3.97 million. , The shares were ... with the Securities and Exchange Commission that was declared effective ...
Cached Medicine Technology:Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 2Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 3Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 4Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering 2
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair ... the forefront of using beard hair to fill in ... a novelty has now become an absolute option for giving patients ... really do believe that beard to scalp hair transplant can be ... area isn’t as dense as we would like it,” says Dr. ...
(Date:3/31/2015)... CT (PRWEB) March 31, 2015 Calling all ... against Lyme and other tick-borne diseases! The first annual “Lyme ... Cove Island Park in Stamford, CT. The event, hosted by ... (TBDA), will raise funds to support research and education ... event, open to all ages and abilities, will feature 5K ...
(Date:3/31/2015)... 2015 OnChip Devices , a world ... silicon ESD diode chip targeted towards low voltage LED applications. ... Zeners are ideal for protecting circuits by suppressing voltage higher ... handle pulses of up to 350W and 20A, providing protection ... 61000-4-2 standard. These diodes do not exhibit any device ...
(Date:3/31/2015)... Scotch Plains, NJ (PRWEB) March 31, 2015 ... a board certified dermatologist by the American Board ... surgeon. After extensive dermatology research training at the ... Health, Dr. Li completed his internship in internal ... at the University of Pennsylvania in Philadelphia. Dr. ...
(Date:3/31/2015)... Dr. Uzma Parvez is having a busy ... conducted Grand Grounds Presentations at St. Michael’s Medical Center for ... Effects”. The event was attended by a large gathering ... positive feedback from the Grand Rounds. It was said ... in a while. , Ahead, Dr. Parvez has been ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Dr. Andrew Li of Warren Skin Care Center Is Celebrating 3 Years Recognized as an "NJ Top Doc" 2Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2
... and none other than ‘gen–present’ and ‘gen-next’ can perfectly relate ... waters continue unabated, people are caught in a frenetic pace, ... seeking newer excitement propelled by desires of a ‘picture-postcard’ life ... is unacceptable - a mute submission to the vagaries of ...
... top Australian researchers have predicted what they hope to be ... transform the way patients are treated, within a period of ... have little choice but to take preventive action when faced ... John Shine, the executive director of the Garvan Institute of ...
... and Locker, Inc. conducted a voluntary recall of over 5,000 ... to alert consumers //of probable beef contamination that was processed ... President Jim Goeser said, "We should note that we have ... certified lab but the voluntary recall must proceed." ,It ...
... Pittsburgh by a team of scientists to study the people aged ... of their long life and to develop tactics to conquer the ... people. ,"The longer we wait, the more they're going ... Coles, the foundation's treasurer and a researcher who has studied the ...
... first death caused by dengue fever in Andhra Pradesh. ... of the state. ,Venkateswara Rao, director (medical ... Puttaparthi in Anantapur district. Two cases in Hyderabad, one ... dengue cases. ,Unofficial reports from different parts ...
... mental fog and forgetfulness and can no longer explain it ... new UCLA study shows that chemotherapy causes changes to the ... 10 years after treatment. Reported Oct. 5 in the online ... findings may help to explain the disrupted thought processes and ...
Cached Medicine News:Health News:Mental Health: Mind at Peace or in Pieces? 2Health News:Mental Health: Mind at Peace or in Pieces? 3Health News:Mental Health: Mind at Peace or in Pieces? 4Health News:Genetics to bring about Medical Breakthroughs 2Health News:Precautionary Recall of Beef over E.coli Contamination Concerns 2Health News:Supercentenarian Center to study longevity 2Health News:First confirmed Dengue death in Andhra Pradesh 2Health News:Chemotherapy's Effects on the Brain 2Health News:Chemotherapy's Effects on the Brain 3
Instrument set for carpal tunnel release....
Standard arthroscopy graspers for small joints. Also available are Mosquito Tip Graspers, 45 degree Forceps, SquareTrimmer Blunt Tip Forceps and SST Scoop Tip Forceps....
... SR™ Hand Implant System utilizes the same ... joint replacements. The SR™ Hand Implant ... other prostheses including minimal bone resection, surface ... articular surfaces, retention and/or repositioning of the ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
Medicine Products: